Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of a Single Low-dose Primaquine for the Clearance of Gametocytes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age of 1 year and above and neither pregnant nor breast feeding.~* Weight over 10 kg.~* Body temperature ≥37.5°C) or history of fever in the last 24 hours.~* P. falciparum mono-infection.~Exclusion Criteria:~* Evidence of severe illness malaria or danger signs.~* Known allergy to study medications.~* Hemoglobin \<8 g/dl.~* Antimalarials taken within last 2 weeks.~* Blood transfusion within last 90 days and evidence of recent use (within 14 days)of or will be taking other drugs known to cause hemolysis in G6PD deficient subjects.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- artemether-lumefantrine+placebo (Type: ACTIVE_COMPARATOR): In the artemether-lumefantrine arm, the first dose of artemether-lumefantrine will be administered concomitantly with a single-dose placebo. A volume of normal saline will be measured based on weight bands and then will be given to patients.
- artemether-lumefantrine+primaquine (Type: EXPERIMENTAL): All the recruited patients will be treated with a six doses, 3 days artemether-lumefantrine treatment regimen. However, patients randomized to the artemether-lumefantrine+primaquine arm will be given 0.25 mg/kg single-dose primaquine concomitantly with artemether-lumefantrine first dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).